INSM vs. PTCT, CCXI, TGTX, FTSV, SDGR, VTRS, UTHR, SRPT, RDY, and CTLT
Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include PTC Therapeutics (PTCT), ChemoCentryx (CCXI), TG Therapeutics (TGTX), Forty Seven (FTSV), Schrödinger (SDGR), Viatris (VTRS), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), and Catalent (CTLT). These companies are all part of the "medical" sector.
PTC Therapeutics (NASDAQ:PTCT) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
PTC Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
PTC Therapeutics presently has a consensus target price of $35.67, suggesting a potential downside of 1.83%. Insmed has a consensus target price of $56.38, suggesting a potential upside of 1.93%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than PTC Therapeutics.
PTC Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
PTC Therapeutics has a net margin of -62.45% compared to PTC Therapeutics' net margin of -236.74%.
In the previous week, Insmed had 55 more articles in the media than PTC Therapeutics. MarketBeat recorded 67 mentions for Insmed and 12 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.76 beat Insmed's score of 0.48 indicating that Insmed is being referred to more favorably in the news media.
PTC Therapeutics received 25 more outperform votes than Insmed when rated by MarketBeat users. However, 65.23% of users gave Insmed an outperform vote while only 61.83% of users gave PTC Therapeutics an outperform vote.
Summary
Insmed beats PTC Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Insmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
